{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:44Z","timestamp":1753891544367,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Acute disseminated encephalomyelitis (ADEM) is an autoimmune disorder of the central nervous system (CNS), which is commonly associated to previous viral infection or immunization. Cases of ADEM with a potential relationship to both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have been reported. We recently published a rare case of a 65-year-old patient who suffered from a corticosteroid- and immunoglobulin-refractory multiple autoimmune syndrome including ADEM following Pfizer-BioNTech coronavirus disease (COVID)-19 vaccination, and whose symptoms largely resolved after repeated plasma exchange (PE). Four months later, the patient was diagnosed with SARS-CoV-2 omicron variant infection after experiencing mild upper respiratory tract symptoms. Few days later, the patient developed severe tetraparesis with magnetic resonance imaging (MRI) showing multiple new inflammatory contrast-enhancing lesions in the left middle cerebellar peduncle, cervical spinal cord, and ventral conus medullaris. Repeated cerebrospinal fluid (CSF) analyses indicated blood-brain barrier damage (increased albumin ratio) without signs of SARS-CoV-2 invasion (mild pleocytosis, no intrathecal antibody production). SARS-CoV-2 specific immunoglobulin G (IgG) were detected in serum and to a much lower degree in CSF with close correlation between both concentrations over time, reflecting antibody dynamics of vaccine- and infection-induced immune response, and blood-brain barrier patency. Daily PE therapy was initiated. Given the patient's lack of improvement after seven PE, treatment with rituximab was considered. After a first dose, however, the patient suffered epididymo-orchitis leading to sepsis, and declined rituximab continuation. At 3-months follow-up, clinical symptoms had dramatically improved. The patient regained walking ability without assistance. This case of recurrent ADEM after COVID-19-vaccination and after subsequent COVID-19-infection strongly supports the hypotheses of neuroimmunological complications in these conditions being promoted by a systemic immune response and mediated by molecular mimicry of, both, viral and vaccine SARS-CoV-2 antigens and CNS self-antigens.<\/jats:p>","DOI":"10.3389\/fneur.2023.1149612","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T04:50:04Z","timestamp":1678423804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II)"],"prefix":"10.3389","volume":"14","author":[{"given":"Khouloud","family":"Poli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kowarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Hamprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Iftner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Ernemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2019.06.017","article-title":"Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria","volume":"100","author":"Cole","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e797","DOI":"10.1212\/NXI.0000000000000797","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 infection","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00415-021-10771-8","article-title":"SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature","volume":"269","author":"Wang","year":"2022","journal-title":"J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e936574","DOI":"10.12659\/AJCR.936574","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination","volume":"23","author":"Ahmad","year":"2022","journal-title":"Am J Case Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"106839","DOI":"10.1016\/j.clineuro.2021.106839","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination","volume":"208","author":"Vogrig","year":"2021","journal-title":"Clin Neurol Neurosurg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tins.2022.02.006","article-title":"The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2","volume":"45","author":"Bauer","year":"2022","journal-title":"Trends Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"913515","DOI":"10.3389\/fneur.2022.913515","article-title":"Multiple autoimmune syndromes including acute disseminated encephalomyelitis, myasthenia gravis, and thyroiditis following messenger ribonucleic acid-based COVID-19 vaccination: a case report","volume":"13","author":"Poli","year":"2022","journal-title":"Front Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.vaccine.2012.07.024","article-title":"Biologically plausible and evidence-based risk intervals in immunization safety research","volume":"31","author":"Rowhani-Rahbar","year":"2012","journal-title":"Vaccine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/jnnp-2021-326924","article-title":"Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder","volume":"92","author":"Butler","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity."},{"key":"B13","doi-asserted-by":"publisher","first-page":"626235","DOI":"10.3389\/fimmu.2021.626235","article-title":"High levels of circulating IL-8 and soluble IL-2R are associated with prolonged illness in patients with severe COVID-19","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jnc.15459","article-title":"Neurochemical biomarkers to study CNS effects of COVID-19: a narrative review and synthesis","volume":"159","author":"Eden","year":"2021","journal-title":"J Neurochem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2213253","DOI":"10.1001\/jamanetworkopen.2022.13253","article-title":"Viral antigen and inflammatory biomarkers in cerebrospinal fluid in patients with COVID-19 infection and neurologic symptoms compared with control participants without infection or neurologic symptoms","volume":"5","author":"Eden","year":"2022","journal-title":"JAMA Netw Open."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e02890","DOI":"10.1128\/JCM.02890-20","article-title":"Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays","volume":"59","author":"Semmler","year":"2021","journal-title":"J Clin Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2022.05.026","article-title":"Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers","volume":"122","author":"Oliveira-Silva","year":"2022","journal-title":"Int J Infect Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41467-022-29225-4","article-title":"Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors","volume":"13","author":"P\u00e9rez-Al\u00f3s","year":"2022","journal-title":"Nat Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1149612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T04:50:06Z","timestamp":1678423806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1149612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":19,"alternative-id":["10.3389\/fneur.2023.1149612"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1149612","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"article-number":"1149612"}}